Association of the novel CROW-65 risk score and mortality in hospitalized kidney transplant recipients with COVID-19 : A retrospective observational study.
COVID-19
CROW-65 risk score
Early mortality
Kidney transplant recipients
Risk assessment
Journal
Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
27
01
2022
accepted:
03
06
2022
pubmed:
8
7
2022
medline:
16
12
2022
entrez:
7
7
2022
Statut:
ppublish
Résumé
Kidney transplant recipients (KTR) are a group of patients with heterogeneous risks for adverse outcomes with COVID-19, but risk stratification tools in this patient group are lacking. This retrospective observational, hypothesis-generating study included 49 hospitalized adult KTR patients with COVID-19 at the University Hospital of Split (August 2020 to October 2021) and evaluated the performance of novel risk score CROW-65 (age, Charlson Comorbidity Index [CCI] lactate dehydrogenase to white blood cell [LDH:WBC] ratio, and respiratory rate oxygenation [ROX index]). The primary outcome of the study was 30-day postdischarge all-cause mortality. A total of 8 fatal events (16.3%) occurred during the study follow-up. When comparing CROW-65 by survival status, it was significantly increased in patients with fatal event (P < 0.001). Using the Cox proportional hazards regression analysis, the CROW-65 risk score showed statistically significant association with mortality (HR 1.11, 95% CI 1.01-1.23, P = 0.027), while receiving operator characteristics (ROC) showed significant discrimination of all-cause mortality with an AUC of 0.85 (95% CI 0.72-0.94, P < 0.001), and satisfactory calibration (χ A novel risk score CROW-65 showed significant association with all-cause mortality in KTR yielding important hypothesis-generating findings. Further powered studies should reassess the performance of CROW-65 risk score in this population, including predictability, calibration and discrimination.
Sections du résumé
BACKGROUND
BACKGROUND
Kidney transplant recipients (KTR) are a group of patients with heterogeneous risks for adverse outcomes with COVID-19, but risk stratification tools in this patient group are lacking.
METHODS AND PARTICIPANTS
METHODS
This retrospective observational, hypothesis-generating study included 49 hospitalized adult KTR patients with COVID-19 at the University Hospital of Split (August 2020 to October 2021) and evaluated the performance of novel risk score CROW-65 (age, Charlson Comorbidity Index [CCI] lactate dehydrogenase to white blood cell [LDH:WBC] ratio, and respiratory rate oxygenation [ROX index]). The primary outcome of the study was 30-day postdischarge all-cause mortality.
RESULTS
RESULTS
A total of 8 fatal events (16.3%) occurred during the study follow-up. When comparing CROW-65 by survival status, it was significantly increased in patients with fatal event (P < 0.001). Using the Cox proportional hazards regression analysis, the CROW-65 risk score showed statistically significant association with mortality (HR 1.11, 95% CI 1.01-1.23, P = 0.027), while receiving operator characteristics (ROC) showed significant discrimination of all-cause mortality with an AUC of 0.85 (95% CI 0.72-0.94, P < 0.001), and satisfactory calibration (χ
CONCLUSION
CONCLUSIONS
A novel risk score CROW-65 showed significant association with all-cause mortality in KTR yielding important hypothesis-generating findings. Further powered studies should reassess the performance of CROW-65 risk score in this population, including predictability, calibration and discrimination.
Identifiants
pubmed: 35799015
doi: 10.1007/s00508-022-02052-9
pii: 10.1007/s00508-022-02052-9
pmc: PMC9261897
doi:
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
842-849Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.
Références
Gao YD, Ding M, Dong X, Zhang JJ, Azkur KA, Azkur D, et al. Risk factors for severe and critically ill COVID-19 patients: a review. Allergy. 2021;76(2):428–55.
doi: 10.1111/all.14657
Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–6.
doi: 10.1038/s41586-020-2521-4
ERA-EDTA Council, ERACODA Working Group. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrol Dial Transplant. 2021;36(1):87–94.
doi: 10.1093/ndt/gfaa314
Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HHX, Mercer SW, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Health. 2020;8(8):e1003–17.
doi: 10.1016/S2214-109X(20)30264-3
Caillard S, Chavarot N, Francois H, Matignon M, Greze C, Kamar N, et al. Is COVID-19 infection more severe in kidney transplant recipients? Am J Transplant. 2021;21(3):1295–303.
doi: 10.1111/ajt.16424
Raja MA, Mendoza MA, Villavicencio A, Anjan S, Reynolds JM, Kittipibul V, et al. COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis of current literature. Transplant Rev. 2021;35(1):100588.
doi: 10.1016/j.trre.2020.100588
Hilbrands LB, Duivenvoorden R, Vart P, Franssen CFM, Hemmelder MH, Jager KJ, et al. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrol Dial Transplant. 2020;35(11):1973–83.
doi: 10.1093/ndt/gfaa261
Mahalingasivam V, Craik A, Tomlinson LA, Ge L, Hou L, Wang Q, et al. A systematic review of COVID-19 and kidney transplantation. Kidney Int. 2021;6(1):24–45.
Abolghasemi S, Mardani M, Sali S, Honarvar N, Baziboroun M. COVID-19 and kidney transplant recipients. Transpl Infect Dis. 2020;31:e13413.
Azzi Y, Bartash R, Scalea J, Loarte-Campos P, Akalin E. COVID-19 and solid organ transplantation: a review article. Transplantation. 2021;105(1):37–55.
doi: 10.1097/TP.0000000000003523
Jager KJ, Kramer A, Chesnaye NC, Couchoud C, Sánchez-Álvarez JE, Garneata L, et al. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int. 2020;98(6):1540–8.
doi: 10.1016/j.kint.2020.09.006
Cravedi P, Mothi SS, Azzi Y, Haverly M, Farouk SS, Pérez-Sáez MJ, et al. COVID-19 and kidney transplantation: results from the TANGO International Transplant Consortium. Am J Transplant. 2020;20(11):3140–8.
doi: 10.1111/ajt.16185
Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, et al. Imbalanced host response to SARS-CoV‑2 drives development of COVID-19. Cell. 2020;181(5):1036–1045.e9.
doi: 10.1016/j.cell.2020.04.026
Yilmaz G, Ebru O, Ibrahim B, Ulkem C. Assessment of clinical outcomes in renal transplant recipients with COVID-19. J Med Virol. 2021;93(12):6760–4.
doi: 10.1002/jmv.27271
Vishnevetsky A, Levy M. Rethinking high-risk groups in COVID-19. Mult Scler Relat Disord. 2020;42:102139.
doi: 10.1016/j.msard.2020.102139
Modelli de Andrade LG, de Sandes-Freitas TV, Requião-Moura LR, Viana LA, Cristelli MP, Garcia VD, et al. Development and validation of a simple web-based tool for early prediction of COVID-19-associated death in kidney transplant recipients. Am J Transplant. 2022;22(2):610–25.
doi: 10.1111/ajt.16807
Kljakovic Gaspic T, Pavicic Ivelja M, Kumric M, Matetic A, Delic N, Vrkic I, et al. In-hospital mortality of COVID-19 patients treated with high-flow nasal oxygen: evaluation of biomarkers and development of the novel risk score model CROW-65. Life. 2021;11(8):735.
doi: 10.3390/life11080735
Levey AS, Inker LA, Coresh J. GFR estimation: from physiology to public health. Am J Kidney Dis. 2014;63(5):820–34.
doi: 10.1053/j.ajkd.2013.12.006
Setter NW, Peres ML, de Almeida BMM, Petterle RR, Raboni SM. Charlson comorbidity index scores and in-hospital prognosis of patients with severe acute respiratory infections. Intern Med J. 2020;50(6):691–7.
doi: 10.1111/imj.14398
Hosmer DW, Hosmer T, Lemeshow S. A Goodness-of-Fit Tests for the Multiple Logistic Regression Model. Communications in Statistics. 1980;10:1043–69. https://doi.org/10.1080/03610928008827941 .
doi: 10.1080/03610928008827941
Harrell FE, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the Yield of Medical Tests. 1982;247(18):2543–6. https://doi.org/10.1001/jama.1982.03320430047030 .
doi: 10.1001/jama.1982.03320430047030
Hanley J, McNEil B. The Meaning and Use of the Area under a Receiver Operating Characteristic (ROC) Curve. Radiology. 1982:143;29–36. https://doi.org/10.1148/radiology.143.1.7063747 .
doi: 10.1148/radiology.143.1.7063747
King J Jr, Yoon JS, Rentsch CT, Tate JP, Park LS, Kidwai-Khan F, et al. Development and validation of a 30-day mortality index based on pre-existing medical administrative data from 13,323 COVID-19 patients: the Veterans Health Administration COVID-19 (VACO) Index. PLoS ONE. 2020;15(11):e241825–11.
doi: 10.1371/journal.pone.0241825
Knight SR, Ho A, Pius R, Buchan I, Carson G, Drake TM, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ. 2020;370:m3339.
doi: 10.1136/bmj.m3339
Udomkarnjananun S, Kerr SJ, Townamchai N, Susantitaphong P, Tulvatana W, Praditpornsilpa K, et al. Mortality risk factors of COVID-19 infection in kidney transplantation recipients: a systematic review and meta-analysis of cohorts and clinical registries. Sci Rep. 2021;11(1):20073.
doi: 10.1038/s41598-021-99713-y
Lemiale V, Dumas G, Demoule A, Pène F, Kouatchet A, Bisbal M, et al. Performance of the ROX index to predict intubation in immunocompromised patients receiving high-flow nasal cannula for acute respiratory failure. Ann Intensive Care. 2021;11:17.
doi: 10.1186/s13613-021-00801-z
Vidal-Cevallos P, Higuera-De-La-Tijera F, Chávez-Tapia NC, Sanchez-Giron F, Cerda-Reyes E, Rosales-Salyano VH, et al. Lactate-dehydrogenase associated with mortality in hospitalized patients with COVID-19 in Mexico: a multi-centre retrospective cohort study. Ann Hepatol. 2021;24:100338.
doi: 10.1016/j.aohep.2021.100338